Diphenylpyraline

	WikiDoc Resources for Diphenylpyraline
Articles
Most recent articles on Diphenylpyraline Most cited articles on Diphenylpyraline Review articles on Diphenylpyraline Articles on Diphenylpyraline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Diphenylpyraline Images of Diphenylpyraline Photos of Diphenylpyraline Podcasts & MP3s on Diphenylpyraline Videos on Diphenylpyraline
Evidence Based Medicine
Cochrane Collaboration on Diphenylpyraline Bandolier on Diphenylpyraline TRIP on Diphenylpyraline
Clinical Trials
Ongoing Trials on Diphenylpyraline at Clinical Trials.gov Trial results on Diphenylpyraline Clinical Trials on Diphenylpyraline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Diphenylpyraline NICE Guidance on Diphenylpyraline NHS PRODIGY Guidance FDA on Diphenylpyraline CDC on Diphenylpyraline
Books
Books on Diphenylpyraline
News
Diphenylpyraline in the news Be alerted to news on Diphenylpyraline News trends on Diphenylpyraline
Commentary
Blogs on Diphenylpyraline
Definitions
Definitions of Diphenylpyraline
Patient Resources / Community
Patient resources on Diphenylpyraline Discussion groups on Diphenylpyraline Patient Handouts on Diphenylpyraline Directions to Hospitals Treating Diphenylpyraline Risk calculators and risk factors for Diphenylpyraline
Healthcare Provider Resources
Symptoms of Diphenylpyraline Causes & Risk Factors for Diphenylpyraline Diagnostic studies for Diphenylpyraline Treatment of Diphenylpyraline
Continuing Medical Education (CME)
CME Programs on Diphenylpyraline
International
Diphenylpyraline en Espanol Diphenylpyraline en Francais
Business
Diphenylpyraline in the Marketplace Patents on Diphenylpyraline
Experimental / Informatics
List of terms related to Diphenylpyraline

Diphenylpyraline
Clinical data
Synonyms	4-(diphenylmethoxy)-1-methyl-piperidine
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, Topical
ATC code	R06AA07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	24-40 hours
Identifiers
	IUPAC name 4-benzhydryloxy-1-methyl-piperidine;
CAS Number	147-20-6 ;
PubChem CID	3103;
DrugBank	DB01146 ;
ChemSpider	2992 ;
UNII	33361OE3AV;
KEGG	D07862 ;
ChEBI	CHEBI:59788 ;
ChEMBL	ChEMBL1492 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C19H23NO
Molar mass	281.392 g/mol
3D model (JSmol)	Interactive image;
	SMILES O(C(c1ccccc1)c2ccccc2)C3CCN(C)CC3;
	InChI InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3 ; Key:OWQUZNMMYNAXSL-UHFFFAOYSA-N ;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Diphenylpyraline (DPP; sold as Allergen, Arbid, Belfene, Diafen, Hispril, Histyn, Lergobine, Lyssipol, Mepiben, Neargal) is a first-generation antihistamine with anticholinergic effects of the diphenyl piperidine class.^[2]^[3]^[4] It is marketed in Europe for the treatment of allergies.^[2]^[3]^[5] DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents.^[6] It has been shown to be useful in the treatment of Parkinsonism.^[7]

Chemistry

Diphenylpyraline, 4-diphenylmethoxy-1-methylpiperidine, is synthesized by alkylating 4-hydroxy-1-methylpiperidine with benzhydrylbromide.

References

↑ Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID 4156058.
↑ ^2.0 ^2.1 Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
↑ ^3.0 ^3.1 Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. PMID 14039.
↑ Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi:10.1254/jjp.43.277. PMID 2884340.
↑ Hruby, Victor J.; Ruben Vardanyan; Vardanyan, ۊRuben (2006). Synthesis of essential drugs. Amsterdam: Elsevier. ISBN 0-444-52166-6.
↑ Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID 15627433.
↑ Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID 11137513.

Template:Stimulants

[pmid4156058-1] Graham G, Bolt AG (June 1974). "Half-life of diphenylpyraline in man". Journal of Pharmacokinetics and Biopharmaceutics. 2 (3): 191–5. doi:10.1007/BF01059761. PMID 4156058.

[isbn3-88763-075-0-2] 2.0 ^2.1 Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.

[pmid14039-3] 3.0 ^3.1 Puhakka H, Rantanen T, Virolainen E (1977). "Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis". J Int Med Res. 5 (1): 37–41. PMID 14039.

[pmid2884340-4] Kubo N, Shirakawa O, Kuno T, Tanaka C (March 1987). "Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay". Japanese Journal of Pharmacology. 43 (3): 277–82. doi:10.1254/jjp.43.277. PMID 2884340.

[isbn0-444-52166-6-5] Hruby, Victor J.; Ruben Vardanyan; Vardanyan, ۊRuben (2006). Synthesis of essential drugs. Amsterdam: Elsevier. ISBN 0-444-52166-6.

[pmid15627433-6] Lapa G, Mathews T, Harp J, Budygin E, Jones S (2005). "Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties". Eur J Pharmacol. 506 (3): 237–40. doi:10.1016/j.ejphar.2004.11.017. PMID 15627433.

[pmid11137513-7] Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I (2001). "Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients". J Neurol Sci. 182 (2): 95–7. doi:10.1016/S0022-510X(00)00441-X. PMID 11137513.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

v t e Antihistamines (R06)
Aminoalkyl ethers	Bromazine/Bromodiphenhydramine • Carbinoxamine • Clemastine • Chlorphenoxamine • Diphenylpyraline • Diphenhydramine • Doxylamine • Orphenadrine • Phenyltoloxamine
Substituted alkylamines	Brompheniramine • Chlorphenamine • Dexbrompheniramine • Dexchlorpheniramine • Dimetindene • Pheniramine • Talastine
Substituted ethylenediamines	Chloropyramine • Histapyrrodine • Mepyramine • Methapyrilene • Tripelennamine (Pyribenzamine)
Phenothiazine derivatives	Alimemazine • Hydroxyethylpromethazine • Isothipendyl • Mequitazine • Methdilazine • Oxomemazine • Promethazine
Piperazine derivatives	Buclizine • Cetirizine • Chlorcyclizine • Cinnarizine • Cyclizine • Hydroxyzine • Levocetirizine • Meclizine • Niaprazine • Oxatomide
Others for systemic use	Antazoline • Azatadine • Bamipine • Cyproheptadine • Deptropine • Dimebon • Ebastine • Epinastine • Ketotifen • Mebhydrolin • Mizolastine • Phenindamine • Pimethixene • Pyrrobutamine • Rupatadine • Triprolidine • selective (Acrivastine • Astemizole • Azelastine • Desloratadine • Fexofenadine • Loratadine • Terfenadine)
For topical use	Bamipine • Chloropyramine • Chlorphenoxamine • Clemastine • Dimetindene • Diphenhydramine • Isothipendyl • Mepyramine • Promethazine • Thenalidine
Antiallergic agents excluding corticosteroids	Antazoline • Azelastine
Other antiallergics	Emedastine • Epinastine • Ketotifen • Montelukast • Olopatadine

Diphenylpyraline

Overview

Chemistry

See also

References

Navigation menu

Diphenylpyraline

Overview

Chemistry

See also

References

Navigation menu

Search